Advertisement
UK markets closed

  • FTSE 100

    8,275.38
    +44.33 (+0.54%)
     

  • FTSE 250

    20,730.12
    +59.25 (+0.29%)
     

  • AIM

    805.79
    +3.10 (+0.39%)
     

  • GBP/EUR

    1.1742
    -0.0007 (-0.06%)
     

  • GBP/USD

    1.2738
    +0.0006 (+0.05%)
     

  • Bitcoin GBP

    53,171.01
    +256.65 (+0.49%)
     

  • CMC Crypto 200

    1,427.32
    -1.25 (-0.09%)
     

  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     

  • DOW

    38,686.32
    +574.84 (+1.51%)
     

  • CRUDE OIL

    77.18
    -0.73 (-0.94%)
     

  • GOLD FUTURES

    2,347.70
    -18.80 (-0.79%)
     

  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     

  • HANG SENG

    18,079.61
    -150.58 (-0.83%)
     

  • DAX

    18,497.94
    +1.15 (+0.01%)
     

  • CAC 40

    7,992.87
    +14.36 (+0.18%)
     
PROPERTY:

10 bijou homes that are big on style

Size isn’t everything when it comes to buying a home

Veracyte to Participate in Upcoming Investor Conferences

Business Wire
·1-min read

SOUTH SAN FRANCISCO, Calif., May 15, 2024--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences.

  • Leerink Partners 2024 Healthcare Crossroads Conference – Austin, TX
    Fireside Chat on May 29th at 12:20 p.m. Eastern Time

  • William Blair 44th Annual Growth Stock Conference – Chicago, IL
    Presentation on June 4th at 5:40 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcasts will be available following the conclusion of the live presentation broadcast.

ADVERTISEMENT

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515789405/en/

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Tracy Morris
media@veracyte.com
(650) 380-4413